Open an account

Sellas Life Sciences Group

SLS · NASDAQ

$11.98+$1.49 (+14.20%)TodayMarket closed ·
Prev close $10.49

About SLS

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2008-03-12. The firm is focused on the development of therapeutics for a range of cancer indications. The firm's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The firm is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.

Employees
13
Headquarters
New York City, New York
Listed
Mar 12, 2008
Sector
Health Care
Industry
Biotechnology
Website
sellaslifesciences.com

SLS key statistics

Market cap
2.42B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
5.39M
Volume
10.26M
Open price
$10.07
High today
$12.01
Low today
$9.95
52 Week high
$15.88
52 Week low
$1.39

Sellas Life Sciences Group (SLS) at a glance

As of Oct 20, 2026, Sellas Life Sciences Group (SLS) shares are priced at $11.98, giving the company a market cap of 2.42B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $9.95 and $12.01. The current price is 20.4% above the day's low and 0.2% below its high.

Volume so far is 10.26M shares, above the average of 5.39M shares a day.

Over the past year Sellas Life Sciences Group has ranged from $1.39 to $15.88, and now sits 73% of the way up that range.

Sellas Life Sciences Group met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q2 FY26 it reported -$0.05 per share against an estimate of -$0.0455.

The average analyst price target is $33.15, 176.7% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $33.15
Low
$30.30
Now
$11.98
High
$36.75

SLS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 22.3% on average.

  1. Q3 FY24: reported -$0.10 per share against an estimate of -$0.1313
  2. Q4 FY24: reported -$0.08 per share against an estimate of -$0.1084
  3. Q1 FY25: reported -$0.07 per share against an estimate of -$0.1061
  4. Q2 FY25: reported -$0.07 per share against an estimate of -$0.0832
  5. Q3 FY25: reported -$0.06 per share against an estimate of -$0.0667
  6. Q4 FY25: reported -$0.05 per share against an estimate of -$0.0657
  7. Q1 FY26: reported -$0.05 per share against an estimate of -$0.0404
  8. Q2 FY26: reported -$0.05 per share against an estimate of -$0.0455

SLS news

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLS

  • Radhika Anilkumar Nadig

    SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerously Wrong: 'Most Expensive Coin Flip' (UPDATED)

Similar companies

Companies in the same industry as Sellas Life Sciences Group

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.